Core-based scientist specializing in high throughput screening for early drug discovery, target identification and systems biology analysis of cancer

专注于癌症早期药物发现、靶标识别和系统生物学分析的高通量筛选的核心科学家

• 批准号: 10469395
• 负责人: Meng Wu
• 金额: $ 18.92万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-01-04 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10469395
• 关键词: 3-Dimensional; Applications Grants; Award; Biochemical; Biological; Biological Assay; Biological Products; Cancer Center Support Grant; Cancer Etiology; Cancer Patient; Cancer Research Project; Cell Culture System; Cell Line; Cells; Chemicals; Clinical Trials; Clustered Regularly Interspaced Short Palindromic Repeats; Coculture Techniques; Collaborations; Communities; Comprehensive Cancer Center; Consequentialism; Core Facility; Data Analyses; Data Set; Detection; Development; Dose; Equipment; FDA approved; Funding; Goals; Guide RNA; Image; Image Analysis; Immune; Iowa; Label; Leadership; Libraries; Maintenance; Malignant Neoplasms; Mentors; Mentorship; Mission; Organoids; Pain; Patients; Peer Review; Pharmaceutical Preparations; Procedures; PubChem; PubMed; Publications; Research; Research Personnel; Resource Sharing; Robotics; Sampling; Scientist; Specialist; Systems Biology; Technical Expertise; Technology; Testing; Therapeutic; Universities; Validation; Wages; assay development; base; data management; detection platform; drug discovery; early screening; evidence base; high throughput screening; novel; precision medicine; ranpirnase; recruit; response; screening; small molecule; translational cancer research

Project Summary: Dr. Meng Wu is Director of the University of Iowa High Throughput Screening Facility (UIHTS), a shared resource of the NCI-designated Holden Comprehensive Cancer Center (HCCC). He is mentored by Dr. George Weiner, Director of the HCCC and PI of Cancer Center Support Grant (CCSG) 5 P30 CA086862-18. Dr. Wu has extensive expertise in high throughput screening, assay development and adaption, fluorescent and label-free detection, the discovery of small-molecule probes and drug leads, high content imaging, and high throughput data analysis; this is evident from his 230 BioAssays in PubChem and 41 publications in PubMed). The UIHTS was established in 2012 by university sponsors including the HCCC. Dr. Wu is the inaugural director of the UIHTS and has overseen the establishment and maintenance of every aspect of the facility, including acquisition of both high throughput and high content imaging equipment, construction of chemical and biological libraries, and establishment of biochemical as well as cell-based standard operating procedures (SOPs). Dr. Wu also streamlined the workflow, from project recruitment, assay development, compound management, high throughput/content screening, data and image analysis, hit-picking and dose-response validation/confirmation, to preliminary datasets for external grant application and final datasets for publication. This effort resulted in integration of the UIHTS into the HCCC as a core facility during its renewal in 2016. Dr. Wu's scientific and administrative leadership of the UIHTS has provided HCCC investigators access to new scientific approaches by a high-throughput platform for integrating robotics, high throughput and high content detection systems, chemical/biologics libraries (small-molecule drugs, arrayed CRISPR gRNAs, and cell lines), data management, and technical expertise. In 2018 alone, the UIHTS core supported 15 NCI-supported projects, among 27 peer reviewed (external funded) cancer research projects, contributing to assay development and high throughput screening. In this NCI R50 proposal, we request salary support for Dr. Wu under Dr. Weiner's mentorship, to support him in the following activities: 1) continued high throughput screening in collaboration with the basic and translational cancer research community, for the discovery of novel probes and therapeutics for cancer patients; 2) development of novel high throughput-compatible assays/technologies (e.g., involving the use of 3D- spheroids, patient-derived organoids, co-culture cell systems) to enable more direct patient-relevant screening approaches; 3) facilitation of systematic, un-biased optimization of synergetic effects of FDA-approved drugs and immune-oncological therapeutics for novel clinical trials; and 4) exploration of the use of patient-derived cells and spheroids in evidence-based precision medicine. Support from the NCI in the form of a Research Specialist Award, together with mentorship and support from the HCCC, will enable Dr. Wu to make a crucial contribution to the overall goals of the HCCC.

项目总结: